‘Rushed’ Drug Development that Aims to Refill Pharma Firms’ Pipelines Is Less Likely to Succeed Because of Inter-organizational Friction

When a large pharmaceutical company experiences a drug trial failure and then tries to refill its pipeline by licensing a product created by another firm, such a “rushed innovation” is less likely to bring a product to market than one developed under normal, less hurried conditions. That’s because the hastily drawn licensing agreement between the two organizations leads to friction that drags development work to a halt.

Rutgers Expert Available to Discuss How to Help Free Market Fight Coronavirus

New Brunswick, N.J. (March 25, 2020) – Stephen K. Burley, director of the RCSB Protein Data Bank headquartered at Rutgers University–New Brunswick, is available for interviews on how to help the free market fight the coronavirus. His viewpoint is published in the journal Nature. “Had drug…

Expert on #FDA’s #Expanded Access program: Cost can be a barrier to critically ill patients, healthcare providers, and others seeking to try experimental treatments as a last resort. Dr. Marjorie A. Speers available to comment or participate in inter

Costs related to the expanded access procedure under which critically ill patients can  try experimental drugs, biologics, and medical devices are often overlooked. These costs, according to Clinical Research Pathways Executive Director Marjorie A. Speers, Ph.D. can become a barrier for patients,…